Premium
Endocrinology and Dialysis: Management of Lipid Abnormalities Associated with End‐Stage Renal Disease
Author(s) -
Liu Jia,
Kalantarinia Kambiz,
Rosner Mitchell H.
Publication year - 2006
Publication title -
seminars in dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.899
H-Index - 78
eISSN - 1525-139X
pISSN - 0894-0959
DOI - 10.1111/j.1525-139x.2006.00193.x
Subject(s) - medicine , dyslipidemia , end stage renal disease , dialysis , intensive care medicine , disease , population , kidney disease , environmental health
The management of lipid abnormalities in patients with end‐stage renal disease (ESRD) remains controversial. Large, well‐designed studies investigating the effects of dyslipidemia on cardiovascular (CV) morbidity and mortality and the role of cholesterol lowering drugs in reducing mortality in ESRD patients are lacking. While it seems reasonable to suspect that dyslipidemia and its treatment in ESRD patients will affect CV morbidity and mortality similar to that in the general population, recent studies have suggested that this may not be the case. Furthermore, the pharmacokinetics of lipid lowering drugs are altered in patients with ESRD and must be considered when treating this group of patients. This article reviews the major classes of drugs used to treat dyslipidemia, emphasizing their role in patients with ESRD.